Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 11
2024 483
2025 887
2026 320

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,480 results

Results by year

Filters applied: . Clear all
Page 1
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). European Association for the Study of the Liver (EASL), et al. J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7. J Hepatol. 2024. PMID: 38851997 Free article.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and t …
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic …
Natural history and progression of metabolic dysfunction-associated steatotic liver disease.
Hagström H, Shang Y, Hegmar H, Nasr P. Hagström H, et al. Lancet Gastroenterol Hepatol. 2024 Oct;9(10):944-956. doi: 10.1016/S2468-1253(24)00193-6. Lancet Gastroenterol Hepatol. 2024. PMID: 39243773 Review.
The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. ...
The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previousl …
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).
Do A, Zahrawi F, Mehal WZ. Do A, et al. Nat Rev Drug Discov. 2025 Mar;24(3):171-189. doi: 10.1038/s41573-024-01084-2. Epub 2024 Nov 28. Nat Rev Drug Discov. 2025. PMID: 39609545 Review.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup metabolic dysfunction-associated steatohepatitis (MASH) have become a global epidemic and are driven by chronic overnutrition and multiple genetic su …
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup metabolic …
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F, Kite C, Lagojda L, Dallaway A, Chatha KK, Chaggar SS, Dalamaga M, Kassi E, Kyrou I, Randeva HS. Abdelhameed F, et al. Curr Obes Rep. 2024 Sep;13(3):510-531. doi: 10.1007/s13679-024-00574-z. Epub 2024 May 29. Curr Obes Rep. 2024. PMID: 38809396 Free PMC article. Review.
The introduction of new NAFLD terminology, namely metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently metabolic dysfunction-associated steatotic liver disease (MASLD), has initiated a debate on the interchangeab …
The introduction of new NAFLD terminology, namely metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently metaboli …
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms.
Steinberg GR, Valvano CM, De Nardo W, Watt MJ. Steinberg GR, et al. J Hepatol. 2025 Aug;83(2):584-595. doi: 10.1016/j.jhep.2025.02.033. Epub 2025 Mar 1. J Hepatol. 2025. PMID: 40032040 Free article. Review.
Metabolic dysregulation caused by obesity, insulin resistance, and type 2 diabetes disrupts these pathways, leading to metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). ...
Metabolic dysregulation caused by obesity, insulin resistance, and type 2 diabetes disrupts these pathways, leading to metabolic d …
Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.
Tilg H, Petta S, Stefan N, Targher G. Tilg H, et al. JAMA. 2026 Jan 13;335(2):163-174. doi: 10.1001/jama.2025.19615. JAMA. 2026. PMID: 41212550 Review.
IMPORTANCE: Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a range of liver conditions, progressing from isolated steatosis (characterized by fat accumulation in the liver without inflammation) to metabolic dysf …
IMPORTANCE: Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a range of l …
Pediatric MASLD: current understanding and practical approach.
Stroes AR, Vos M, Benninga MA, Koot BGP. Stroes AR, et al. Eur J Pediatr. 2024 Nov 19;184(1):29. doi: 10.1007/s00431-024-05848-1. Eur J Pediatr. 2024. PMID: 39560782 Review.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most prevalent chronic liver disease in children in industrialized countries mainly due to the rise in obesity and overweight. ...
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most prevalent chronic …
Molecular mechanisms in MASLD/MASH-related HCC.
Wang X, Zhang L, Dong B. Wang X, et al. Hepatology. 2025 Nov 1;82(5):1303-1324. doi: 10.1097/HEP.0000000000000786. Epub 2024 Feb 13. Hepatology. 2025. PMID: 38349726 Free PMC article. Review.
Liver cancer is the third leading cause of cancer-related deaths and ranks as the sixth most prevalent cancer type globally. NAFLD or metabolic dysfunction-associated steatotic liver disease, and its more severe manifestation, NASH or met …
Liver cancer is the third leading cause of cancer-related deaths and ranks as the sixth most prevalent cancer type globally. NAFLD or met …
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.
Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, Bardsley JK, Beverly EA, Corbin KD, ElSayed NA, Isaacs S, Kanwal F, Pekas EJ, Richardson CR, Roden M, Sanyal AJ, Shubrook JH, Younossi ZM, Bajaj M. Cusi K, et al. Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094. Diabetes Care. 2025. PMID: 40434108 Review.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), is a growing but often unrecognized medical problem for people with diabetes (particularly type 2 diabetes …
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoh …
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, Paik JM. Younossi ZM, et al. Clin Gastroenterol Hepatol. 2024 Oct;22(10):1999-2010.e8. doi: 10.1016/j.cgh.2024.03.006. Epub 2024 Mar 21. Clin Gastroenterol Hepatol. 2024. PMID: 38521116
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction associated steatotic liver disease (MASLD), is closely associated with type 2 diabetes (T2D). ...
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction associated steat …
1,480 results